Page last updated: 2024-11-08

cedrene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

cedrene: major constituent of cedarwood oil [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

cedr-8-ene : A sesquiterpene that is cedrane which has a double bond between positions 8 and 9. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6431015
CHEBI ID10216
MeSH IDM0040490

Synonyms (47)

Synonym
(1s,2r,5s,7s)-2,6,6,8-tetramethyltricyclo[5.3.1.0(1,5)]undec-8-ene
CHEBI:10216
[3r-(3alpha,3abeta,7beta,8aalpha)]-2,3,4,7,8,8a-hexahydro-3,6,8,8-tetramethyl-1h-3a,7-methanoazulene
(-)-alpha-cedrene
11028-42-5
1h-3a,7-methanoazulene, 2,3,4,7,8,8a-hexahydro-3,6,8,8-tetramethyl-, [3r-(3.alpha.,3a.beta.,7.beta.,8a.alpha.)]-
cedr-8-ene
(-)-.alpha.-cedrene
brn 3196861
laevo-alpha-cedrene
einecs 207-418-4
(3r-(3alpha,3abeta,7beta,8aalpha))-2,3,4,7,8,8a-hexahydro-3,6,8,8-tetramethyl-1h-3a,7-methanoazulene
1h-3a,7-methanoazulene, 2,3,4,7,8,8a-hexahydro-3,6,8,8-tetramethyl-, (3r,3as,7s,8as)-
levo-alpha-cedrene
cedrene
469-61-4
alpha-cedrene
(-)-alpha-cedrene, >=95.0% (sum of enantiomers, gc)
LMPR0103690006
cas-469-61-4
tox21_302305
dtxcid801022504
NCGC00256204-01
dtxsid0047032 ,
(1s,2r,5s)-2,6,6,8-tetramethyltricyclo[5.3.1.01.5]undec-8-ene
(3r,3as,7s,8as)-3,6,8,8-tetramethyl-2,3,4,7,8,8a-hexahydro-1h-3a,7-methanoazulene
50d4a81g8t ,
unii-50d4a81g8t
3-05-00-01095 (beilstein handbook reference)
.alpha.-cedrene
IRAQOCYXUMOFCW-OSFYFWSMSA-N
W-108691
(3r-(3.alpha.,3a.beta.,7.beta.,8a.alpha.))-2,3,4,7,8,8a-hexahydro-3,6,8,8-tetramethyl-1h-3a,7-methanoazulene
levo-.alpha.-cedrene
j5.927g ,
(3r,3as,7s,8as)-2,3,4,7,8,8a-hexahydro-3,6,8,8-tetramethyl-1h-3a,7-methanoazulene
mfcd00063003
AKOS030503768
Q27108601
HY-135190
(-)-cedrene
1h-3a,7-methanoazulene, 2,3,4,7,8,8a-hexahydro-3,6,8,8-tetramethyl-,(3r,3as,7s,8as)-
CS-0109773
(-)--cedrene
BS-42448
a-cedrene 100 microg/ml in methanol
(-)- alpha -cedrene

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The present method was applied successfully to the pharmacokinetic study of α-cedrene after its intravenous (10 mg/kg) and oral (25 mg/kg) administration in male Sprague-Dawley rats."( GC-MS/MS method for the quantification of α-cedrene in rat plasma and its pharmacokinetic application.
Hong, J; Hong, JY; Kim, TH; Lee, BH; Lee, HS; Lee, KM; Yoo, SD, 2013
)
0.39

Bioavailability

ExcerptReferenceRelevance
"4 h) with bioavailability of 48."( In vivo absorption and disposition of α-cedrene, a sesquiterpene constituent of cedarwood oil, in female and male rats.
Jung, BH; Kim, MG; Kim, TH; Lee, HS; Lee, KM; Seok, SH; Shin, BS; Yoo, SD, 2015
)
0.42
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
human urinary metaboliteAny metabolite (endogenous or exogenous) found in human urine samples.
volatile oil componentAny plant metabolite that is found naturally as a component of a volatile oil.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
sesquiterpeneA C15 terpene.
bridged compoundA polycyclic compound in which two rings have two or more atoms in common.
polycyclic olefinA polycyclic hydrocarbon having any number of double bonds.
carbotricyclic compoundA carbopolyclic compound comprising of three carbocyclic rings.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency14.71310.001022.650876.6163AID1224838; AID1224893
estrogen nuclear receptor alphaHomo sapiens (human)Potency0.27540.000229.305416,493.5996AID743075
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (33)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (12.12)18.7374
1990's0 (0.00)18.2507
2000's7 (21.21)29.6817
2010's18 (54.55)24.3611
2020's4 (12.12)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (2.94%)5.53%
Reviews2 (5.88%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other31 (91.18%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]